A Single Center Prospective, Open Label, Pilot Study to Assess Change in Bone Mass Density and Select Bone Turnover Biomarkers in Gilenya Treated Versus Non-Gilenya Treated Ambulatory Subjects With a Relapsing Form of Multiple Sclerosis

Trial Profile

A Single Center Prospective, Open Label, Pilot Study to Assess Change in Bone Mass Density and Select Bone Turnover Biomarkers in Gilenya Treated Versus Non-Gilenya Treated Ambulatory Subjects With a Relapsing Form of Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacodynamics
  • Acronyms MS-BMD
  • Most Recent Events

    • 15 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 15 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 20 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top